(Q46427304)

22 December 2017

title

Antiangiogenics: new therapeutic standards in metastatic kidney cancer (English)

1 reference

22 December 2017

author name string

J-N Cornu

1

1 reference

22 December 2017

M Rouprêt

2

1 reference

22 December 2017

K Bensalah

3

1 reference

22 December 2017

S Oudard

4

1 reference

22 December 2017

J-J Patard

5

1 reference

22 December 2017

language of work or name

French

0 references

publication date

1 July 2008

1 reference

22 December 2017

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

published in

1 reference

22 December 2017

volume

18 Suppl 4

1 reference

22 December 2017

page(s)

S69-76

1 reference

22 December 2017

Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

CCR drug updates: sorafenib and sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Sorafenib for the treatment of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Temsirolimus in the treatment of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

New challenges in kidney cancer therapy: bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Identification of the von Hippel-Lindau disease tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

The genetic basis of cancer of the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

BAY 43-9006: preclinical data

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

Molecular basis of the VHL hereditary cancer syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2973665-0

7 January 2021

10.1016/S1166-7087(08)73665-0

Identifiers

DOI

1 reference

22 December 2017

release_hjzwgxeudfbghmavw7kj5e5iia

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hjzwgxeudfbghmavw7kj5e5iia

24 November 2022

mapped directly with Wikidata item

1 reference

22 December 2017